Get the complete picture.
Simply click on two cards to find a match, which will reveal part of the picture. Keep playing until you see the complete picture. Use the above tabs to learn more about PREPOPIK® and to order patient savings.
In a head-to-head noninferiority clinical trial* comparing Split-Dose PREPOPIK® vs a Day-Before comparator (2L PEG+E plus 2 x 5 mg bisacodyl tablets):
- 84% of PREPOPIK® patients achieved excellent or good overall visualization of the colon (primary endpoint) vs 74% of patients for the comparator.1
- 96% of patients said they would take PREPOPIK® again and 89% found PREPOPIK® very easy or easy to take vs 55% and 29%, respectively, for the comparator.1 Click here for additional study data.
*
Split-Dose PREPOPIK® was studied in a head-to-head trial to demonstrate noninferiority with the Day-Before Regimen of 2L PEG+E plus 2 x 5 mg bisacodyl tablets. The primary efficacy endpoint was the proportion of patients with successful colon cleansing, defined as bowel preparation with >90% of the mucosa seen and mostly liquid stool, assessed by blinded colonoscopists using a modified Aronchick scale. The secondary endpoints were the quality of cleansing
of the ascending, mid (transverse and descending), and rectosigmoid segments of the colon using the Ottawa scale. Patients were considered to be successfully cleansed after administration of prescribed treatment if colon cleansing on the Ottawa Scale was rated excellent, good or fair. Patients were also required to complete a questionnaire about orange-flavored PREPOPIK®, which included the questions: "Would you ask your doctor for this preparation again if you needed another colonoscopy?" and "How easy or difficult was it to consume the prescribed bowel preparation?"
Reference: 1. Rex DK, Katz PO, Bertiger G, et al. Split-dose administration of a dual-action, low-volume bowel cleanser for colonoscopy: the SEE CLEAR I study. Gastrointest Endosc. 2013;78(1):132-141.
